Relationship of cyclin D1 and P16 with the biological characters of lung cancer

Hong QIU; Changqing SU

ABSTRACT

BACKGROUND:

Cyclin D1 and P16 promote cellular proliferation and inhibit cellular division by regulating the activity of CDK4. There existes to some extent amplification or overexpression of cyclin D1 gene together with P16 gene the inactivation of P16 gene in the many tumors.

OBJECTIVE:

To probe into the relationship of the amplification of cyclin D1 and the deletion of P16 and lung cancer.

DESIGN:

Controlled trial of case samples.

SETTING:

Department of Biochemistry, the 81 Hospital of Chinese PLA.

PARTICIPANTS:

Tissue samples of 40 cases of lung cancer were obtained from surgical specimens of tumor tissues and normal lung tissues at the 81 hospital of Chinese PLA between June 1998 and June 1999. Informed consent was obtained from the patients.

METHODS:

Method of multiplex polymerase chain reaction (PCR) was adopted. Cyclin D1 gene and P16 gene were amplified in the same tube,using extracted genome DNA as template. 10 μL PCR products were separated on a 15 g/L agarose gel.MAIN OUTCOME

MEASURES:

① Amplificative result of cyclin D1and P16 in the pathological tissue of the patients with lung cancer. ② Relationship of cyclin D1 and P16 and the biological character of lung cancer.

RESULTS:

① The amplified positive rates of cyclin D1 gene and P16gene in lung cancer were 55.0%(22/40) and 65%(26/40) respectively.②Relationship of cyclin D1 and P16 and biological characters of lung cancerThe amplified positive rate of both of them is closely related to the metastasis of lymph node and the staging of clinical pathology. With the incidence and development of metastasis, amplification positive rate of cyclin D1 was increased while the positive rate of P16 decreased.

CONCLUSION:

The high amplification of Cyclin D1 and the high deletion of P16 gene is closely related to the high activity of proliferation of lung cancer. To detect the changes of these two genes would help us to judge the metastasis, malignant extent and patients' prognosis.